CN116173217A - Use of vitamin D receptor agonists for the treatment of motor neuron diseases - Google Patents

Use of vitamin D receptor agonists for the treatment of motor neuron diseases Download PDF

Info

Publication number
CN116173217A
CN116173217A CN202310199503.5A CN202310199503A CN116173217A CN 116173217 A CN116173217 A CN 116173217A CN 202310199503 A CN202310199503 A CN 202310199503A CN 116173217 A CN116173217 A CN 116173217A
Authority
CN
China
Prior art keywords
vitamin
motor neuron
medicament
mice
receptor agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310199503.5A
Other languages
Chinese (zh)
Inventor
白戈
刘华清
唐明敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University ZJU
Original Assignee
Zhejiang University ZJU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University ZJU filed Critical Zhejiang University ZJU
Priority to CN202310199503.5A priority Critical patent/CN116173217A/en
Publication of CN116173217A publication Critical patent/CN116173217A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides application of a vitamin D receptor agonist in preparing a product for treating motor neuron diseases, and relates to the technical field of medicines. The inventor researches show that the vitamin D receptor agonist can obviously up-regulate the transcription level of VEGF and improve peripheral nerve and muscle lesions of fibula muscular atrophy and motor nerve dysfunction. Thus, vitamin D receptor agonists can be used in the preparation of products for the treatment of motor neuron diseases.

Description

Use of vitamin D receptor agonists for the treatment of motor neuron diseases
Technical Field
The invention relates to the technical field of medicines, in particular to application of a vitamin D receptor agonist in preparing a product for treating motor neuron diseases.
Background
In the past few decades, the social burden caused by global nervous system diseases has shown a significant upward trend. Taking 2015 as an example, various nervous system diseases all over the world lead to death of 940 ten thousand patients, accounting for 16.8% of the total population of deaths, which is the lethal factor of rank 2. Among these neurological diseases, the most causative causes remain unclear until now. Fibular muscular dystrophy (CMT), one of the most common hereditary peripheral neuropathy, has a prevalence of about 1:2500 worldwide. The clinical symptoms of patients often manifest as loss of strength and muscular atrophy of the distal muscles of the extremities, and impaired motor and sensory functions. The common onset of fibular muscular atrophy is early, and many patients begin to develop clinical symptoms from teenagers or young age stages, and the disease becomes so severe as to lose labor and life self-care capacity with the increasing age. CMT has high incidence and serious illness, and brings heavy burden to families and society of patients, but effective therapeutic drugs are still lacking clinically up to the present time.
Aminoacyl tRNA synthetases are the largest gene family associated with CMT (Patzko and Shy, 2011). Among them, the GARS encoding glycyl tRNA synthetases (GlyRS) are the first members to be discovered, whose mutations lead to a dominant axonal form of CMT (CMT 2D subtype). Although GlyRS function is essential in all cells, mutation of this gene results in selective degenerative changes of peripheral axons, resulting in loss of distal motor/sensory function. We have found that CMT2D mutation alters the conformation of GlyRS, causing mutation of GlyRS (GlyRS CMT2D ) Being able to bind to the Nrp1 receptor and disrupt the Vascular Endothelial Growth Factor (VEGF)/Nrp 1 pathway, down-regulating Nrp1 gene expression exacerbates CMT mouse phenotype, while increasing VEGF expression can improve motor function. Many evidences indicate that VEGF has neuroprotective effects and can reduce the effects of factors such as oxidative stress, nutrient deficiency, chemical toxicity, etc. on neuronal survival and function. Motor neurons express the Nrp1 receptor, which appears to depend on muscle-derived VEGF to sustain survival, and promoter mutations reduce VEGF levels, resulting in delayed motor neuron degeneration. These experiments confirm GlyRS CMT2D Proteins interfere with the VEGF/Nrp1 signaling pathway by interacting with Nrp1 abnormalities, thereby causing motor neurodegeneration.
However, there is currently a lack of effective therapeutic agents against peripheral nerve diseases such as CMT.
In view of this, the present invention has been made.
Disclosure of Invention
It is a first object of the present invention to provide the use of a vitamin D receptor agonist in the manufacture of a product for the treatment of motor neuron diseases, to address at least one of the above problems.
A second object of the present invention is to provide a medicament for treating motor neuron diseases.
In a first aspect, the present invention provides the use of a vitamin D receptor agonist in the manufacture of a product for the treatment of motor neuron diseases.
As a further aspect, the vitamin D receptor agonist comprises calcipotriol.
As a further aspect, the motor neuron disease comprises fibular muscular dystrophy.
As a further aspect, the product comprises a medicament.
In a second aspect, the present invention provides a medicament for the treatment of motor neuron diseases, the medicament comprising a vitamin D receptor agonist.
As a further aspect, the vitamin D receptor agonist comprises calcipotriol.
As a further aspect, the motor neuron disease comprises fibular muscular dystrophy.
As a further technical scheme, the raw materials of the medicine also comprise pharmaceutically acceptable auxiliary materials.
As a further technical scheme, the auxiliary materials comprise at least one of diluents, fillers, excipients, binders, wetting agents, disintegrating agents, absorption promoters, surfactants, adsorption carriers, lubricants and flavoring agents.
As a further technical scheme, the medicament is an oral preparation or an injection.
Compared with the prior art, the invention has the following beneficial effects:
the inventor researches show that the vitamin D receptor agonist can obviously up-regulate the transcription level of VEGF and improve peripheral nerve and muscle lesions of fibula muscular atrophy and motor nerve dysfunction. Thus, vitamin D receptor agonists can be used in the preparation of products for the treatment of motor neuron diseases.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the description of the embodiments or the prior art will be briefly described, and it is obvious that the drawings in the description below are some embodiments of the present invention, and other drawings can be obtained according to the drawings without inventive effort for a person skilled in the art.
FIG. 1 is a schematic representation of the mechanism by which vitamin D receptor agonists (calcipotriol) effect treatment of fibular muscular dystrophy;
FIG. 2 is a graph showing that vitamin D receptor agonists (calcipotriol) can up-regulate VEGF transcription levels in C2C12 cells;
FIG. 3 is a graph showing that vitamin D receptor agonists (calcipotriol) up-regulate VEGF transcription levels in fibular muscle tissue of CMT model mice;
FIG. 4 is a graph showing that calcipotriol significantly increases hind limb extension scores in mice with models of fibular muscular dystrophy;
FIG. 5 is a graph showing that vitamin D receptor agonist (calcipotriol) can significantly prolong the duration of stay on the rotating stick in mice with models of fibular muscular atrophy;
figure 6 shows that calcipotriol has no effect on mouse body weight;
FIG. 7 is a graph of calcipotriol that can significantly increase the rate of sural innervation in mice model for sural muscular atrophy;
figure 8 is that calcipotriol can significantly increase the rate of large diameter axons around the peripheral nerve of mice model for fibular muscular atrophy.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to embodiments and examples, but it will be understood by those skilled in the art that the following embodiments and examples are only for illustrating the present invention and should not be construed as limiting the scope of the present invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention. The specific conditions are not specified, and the process is carried out according to conventional conditions or conditions suggested by manufacturers. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
The inventor researches find that Vitamin D Receptor (VDR) is a transcription regulator of VEGF, and the activation of VDR can significantly up-regulate VEGF expression, so that the target VDR is expected to improve the neuropathy of CMT. According to the invention, the VDR agonist provided by the invention can obviously up-regulate the transcription level of VEGF, improve the disease phenotype of CMT, can be used for treating CMT, and provides a reference for developing effective treatment and prevention of CMT neuropathy.
In a first aspect, the present invention provides the use of a vitamin D receptor agonist in the manufacture of a product for the treatment of motor neuron diseases.
The inventor researches show that the vitamin D receptor agonist can obviously up-regulate the transcription level of VEGF and improve peripheral nerve and muscle lesions of fibula muscular atrophy and motor nerve dysfunction. Thus, vitamin D receptor agonists can be used in the preparation of products for the treatment of motor neuron diseases.
In some preferred embodiments, the motor neuron disease comprises fibular muscular dystrophy.
In some preferred embodiments, the vitamin D receptor agonist includes, but is not limited to, calcipotriol, preferably calcipotriol.
The mechanism by which vitamin D receptor agonists (calcipotriol) effect treatment of fibular muscular dystrophy is shown in figure 1. According to the research of the invention, calcipotriol can enhance VEGF/Nrp1 signals in motor nerves by regulating the expression of VEGF in surrounding tissues, thereby resisting GlyRS CMT2D Is effective in improving motor function of CMT mice.
In some preferred embodiments, the product comprises a medicament.
In a second aspect, the present invention provides a medicament for the treatment of motor neuron diseases, the medicament comprising a vitamin D receptor agonist.
Because the medicine provided by the invention contains vitamin D receptor agonists, the medicine has therapeutic effect on motor neuron diseases.
In some preferred embodiments, the vitamin D receptor agonist is calcipotriol.
In some preferred embodiments, the motor neuron disease is fibula atrophy.
In some preferred embodiments, pharmaceutically acceptable excipients are also included in the raw materials of the medicament.
In some preferred embodiments, the adjuvant includes, but is not limited to, diluents, fillers, excipients, binders, humectants, disintegrating agents, absorption enhancers, surfactants, adsorption carriers, lubricants, or flavoring agents.
In some preferred embodiments, the pharmaceutical dosage form is an oral or injectable formulation.
Preferably, the oral agent comprises: at least one of tablets, granules, dripping pills, soft capsules, suspending agents, solutions and syrups;
preferably, the injection comprises: at least one of dry powder, solution type injection, suspension type injection, and emulsion type injection.
The invention is further illustrated by the following specific examples, however, it should be understood that these examples are for the purpose of illustration only in greater detail and are not to be construed as limiting the invention in any way.
In the following examples, all statistical analyses were performed using GraphPad Prism software. The comparison of the two independent experimental groups adopts t-test, the comparison of the single independent variable group adopts single-factor analysis of variance, and the comparison of the two independent variable groups (mouse model and treatment method) adopts double-factor analysis of variance. All statistical tests were performed on at least 3 biological replicates. P <0.05 was considered significant. The graphs are expressed as mean ± standard deviation unless otherwise indicated.
Example 1 vitamin D receptor agonists can increase the transcript levels of VEGF in C2C12 cells
The method comprises the following steps: C2C12 mouse myoblasts were cultured in DMEM (containing 10% heat-inactivated fetal bovine serum and penicillin-streptomycin) cell culture medium. On the day of the experiment, cells were treated with 10nM calcipotriol or 0.1% dmso (control) for 1 hour, collected for RNA extraction, and then the expression level of VEGF was detected using real-time fluorescent quantitative PCR (RT-QPCR), as shown in fig. 2 (independent replicates, p <0.001 compared to control).
Results: the rapid increase in VEGF expression within 1 hour of calcipotriol treatment of C2C12 cells suggests that VEGF is a direct downstream target gene for VDR.
Example 2 vitamin D receptor agonists can increase VEGF transcription levels in the fibula muscle tissue of CMT model mice
The method comprises the following steps: method for establishing model mice, for post-natal day 6 CMT model mice (carrying GlyRS P234KY Mutant genes) were randomly grouped and intraperitoneally injected with physiological saline (0.1% DMSO) and calcipotriol (60. Mu.g/kg), respectively. Mice were sacrificed 24h later and fibular muscle tissue was removed, mRNA from the tissue was extracted using Trizol method, and the transcript levels of VEGF in the tissues of mice from different treatment groups were then detected and counted using RT-QPCR as shown in fig. 3 (number of mice = 4 for each treatment group compared to control group, p<0.05 Shown in the drawings).
Results: calcipotriol can significantly up-regulate VEGF transcript levels in fibular muscle tissue in CMT model mice.
Example 3 behavioral effects of calcipotriol on CMT model mice
The method comprises the following steps: method for establishing model mice, CMT model mice (carrying GlyRS) P234KY Mutant gene) and wild type mice were individually grouped, and a control group of calcipotriol (60 μg/kg) was intraperitoneally injected with physiological saline (0.1% DMSO) from day 6 of birth of the animals, administered for five days a week and at rest for two days, and administered to the end of 7 weeks of age. Behavioural tests were performed weekly during dosing to assess the effect of the drug on motor function, including hindlimb extension scoring, stick rotation experiments, and the like. And the influence of the drug on the weight of the mice is detected, so that the toxicity of the drug is examined, and the specific implementation method is as follows:
hind limb skeletal muscle disorders were assessed using hind limb stretch scores: the tail of the mice was lifted and the hind limb extension was observed, and the hind limb extension was rated as 2 points, the hind limb extension was rated as 1.5 points, the hind limb extension was rated as 1 point, the hind limb extension was rated as 0.5 points, the hind limb extension was rated as 0 point, and 3 effective data were obtained each time. The mice in the different treatment groups were examined one hour after drug injection and evaluated for skeletal muscle dysfunction in hind limbs as shown in fig. 4 (showing the results of the evaluation of mice at 7 weeks of age, mice in each treatment group were.
The rotating rod experiment is used for evaluating coordination, balance force and movement function conditions: the mice are placed on a stick rotating instrument, the rotating speed and the acceleration are set to be 0.2 r/s, the falling time of the mice is observed and recorded after the instrument is operated, and each time is repeated three times, and each time interval is more than 30min. The mice in the different treatment groups were tested one hour after drug injection and were evaluated for differences in motor function, as shown in fig. 5 (showing the results of the evaluation of mice at 7 weeks of age, with more than or equal to 10 mice in each treatment group, p <0.05 compared to the control group).
And the final period of the experiment is used for carrying out statistical analysis on the weight of the mice, and the result shows that the carbotriol has no significant effect on the weight of the mice, as shown in fig. 6 (showing the evaluation result of the mice at 7 weeks of age, the number of mice in each treatment group is more than or equal to 10, and the p is less than 0.05 compared with the control group).
Results: calcipotriol can significantly improve peripheral nerve function defects of fibular muscular atrophy, and has no side effect on wild mice.
Example 4 Effect of calcipotriol on peripheral neuropathological morphology of CMT model mice
The method comprises the following steps: animal-related grouping and administration treatments were performed as in example 3, and tissue of 7-week-old CMT mice and littermates WT mice were harvested after the end of the behavioral assessment for histopathological examination, including neuromuscular junction innervation, neurite cross-section size and number, etc., as follows:
neuromuscular junction innervation analysis: neuromuscular junctions are points of contact of motor neuron axon terminals on skeletal muscle fibers. Signals transmitted from nerve fibers are transmitted to muscle fibers through joints to regulate contraction and tension of muscles. Muscle atrophy occurs due to nerve fiber degeneration, and is one of the clinical pathological characteristics of fibular muscle atrophy. In the experiment, cervical dislocation of mice in different treatment groups is killed, fibula muscles of the mice are dissected and fixed, and then the mice are sectioned for tissue immunofluorescence staining. The post-synaptic acetylcholine receptor clusters (red) were labeled with R-BTX, NF145 and synaptophysin antibodies to label the nerve fibers. After staining, morphology and co-localization of the nerve fibers and the acetylcholine receptor clusters were observed and counted using a confocal microscope, and at least 5 non-overlapping fields of view were selected for each mouse, containing more than 100 neuromuscular junctions, and the innervation of the muscles was counted, as shown in fig. 7 (a is a neuromuscular junction morphology map; b is a statistic of neuromuscular junction innervation of different morphologies; the number of mice in the group=3, p <0.01 compared to the control group).
Statistics of nerve axon diameter: peripheral nerve synaptosis atrophy is one of the clinical pathological phenomena of fibular atrophy, and thus the improvement of fibular atrophy by drugs is evaluated by diameter of peripheral nerve synapses: the sciatic nerve of the mice was harvested, fixed with 1% osmium acid for 1 hour, and then fixed/stained with 2% uranium acetate aqueous solution for 30 minutes. After dehydration of ethanol at different gradients, the embedding medium+acetone (3:1) was used overnight. Embedding is then carried out at 30-37℃using an embedding agent, and slicing is carried out. Dyeing was performed using dye A (methyl blue 0.52g, blue 0.08g, glycerol 40ml, methanol 40ml,1 Xphosphate buffer 120ml (pH 6.9), purified water 200 ml) at 66℃for 30 minutes, followed by dyeing B (accessory red base 0.2g and 50% ethanol 20ml,380ml purified water) at room temperature for 10-15 minutes. After cleaning and airing, using an electron microscope (790 times mirror) to photograph the cross section of the nerve (more than 5 non-overlapping fields of view are selected); the neurite diameters in each field were counted using ImageJ software and the proportion of neurites with a diameter of the entire cross-section greater than 2 μm was calculated as shown in fig. 8 (a is neurite cross-section; b is neurite proportion count (diameter > 2 μm); number of mice per group = 3, p <0.05 compared to control).
Results: calcipotriol can significantly improve peripheral neuropathological changes in mice with fibular muscle atrophy, and has no side effects on wild mice.
In conclusion, the invention discovers that the vitamin D receptor agonist calcipotriol can obviously up-regulate VEGF transcription level in a fibular muscular atrophy animal model, and improve fibular muscular atrophy peripheral nerve and muscle lesions and motor nerve dysfunction. Moreover, the medicine has no obvious toxicity to normal mice. Thus, calcipotriol has a significant effect in treating muscular dystrophy by up-regulating VEGF transcript levels.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and not for limiting the same; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some or all of the technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit of the invention.

Claims (10)

1. Use of a vitamin D receptor agonist in the manufacture of a product for the treatment of motor neuron diseases.
2. The use according to claim 1, wherein the vitamin D receptor agonist comprises calcipotriol.
3. The use according to claim 1, wherein the motor neuron disease comprises fibular muscular atrophy.
4. The use according to claim 1, wherein the product comprises a medicament.
5. A medicament for treating motor neuron disease, comprising a vitamin D receptor agonist.
6. The medicament of claim 5, wherein the vitamin D receptor agonist comprises calcipotriol.
7. The medicament of claim 5, wherein the motor neuron disease comprises fibular muscular dystrophy.
8. The medicine according to claim 5, wherein the raw materials of the medicine further comprise pharmaceutically acceptable auxiliary materials.
9. The medicament of claim 8, wherein the adjuvant comprises at least one of a diluent, a filler, an excipient, a binder, a wetting agent, a disintegrant, an absorption enhancer, a surfactant, an adsorption carrier, a lubricant, and a flavoring agent.
10. The medicament according to claim 5, wherein the medicament is an oral or injectable preparation.
CN202310199503.5A 2023-02-24 2023-02-24 Use of vitamin D receptor agonists for the treatment of motor neuron diseases Pending CN116173217A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310199503.5A CN116173217A (en) 2023-02-24 2023-02-24 Use of vitamin D receptor agonists for the treatment of motor neuron diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310199503.5A CN116173217A (en) 2023-02-24 2023-02-24 Use of vitamin D receptor agonists for the treatment of motor neuron diseases

Publications (1)

Publication Number Publication Date
CN116173217A true CN116173217A (en) 2023-05-30

Family

ID=86446173

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310199503.5A Pending CN116173217A (en) 2023-02-24 2023-02-24 Use of vitamin D receptor agonists for the treatment of motor neuron diseases

Country Status (1)

Country Link
CN (1) CN116173217A (en)

Similar Documents

Publication Publication Date Title
Lazarov et al. When neurogenesis encounters aging and disease
JP2022084697A (en) Methods and compositions for treating neural degeneration
JP7486328B2 (en) Neurite outgrowth promoter, neuronal dendrite expression promoter, and neurotrophic factor-like substance
KR20200062385A (en) Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones
JP2010504083A (en) Method for growing adult stem cells from blood, especially peripheral blood, and its use in the medical field
Nacimiento et al. Structural changes of anterior horn neurons and their synaptic input caudal to a low thoracic spinal cord hemisection in the adult rat: a light and electron microscopic study
Kolotushkina et al. The influence of Hericium erinaceus extract on myelination process in vitro
CN105602889A (en) Methods and compositions for expanding, identifying, characterizing and enhancing Potency of mammalian-derived glial restricted progenitor cells
Vessal et al. Might astrocytes play a role in maintaining the seizure-prone state?
Read et al. Absence of voltage-dependent calcium channels delays photoreceptor degeneration in rd mice
Matsui et al. Characterization of damage and regeneration in cultured avian utricles
US20100317605A1 (en) The use of epimedium flavones and effective components thereof for the preparation of medicaments of promoting proliferations and differentiations of nerve cells
Hong et al. A novel kindling model of temporal lobe epilepsy in rhesus monkeys induced by Coriaria lactone
CN116173217A (en) Use of vitamin D receptor agonists for the treatment of motor neuron diseases
CN116672466A (en) Application of M1 zone neuron activity inhibitor in preparation of ischemic cerebral apoplexy prevention and treatment drugs
CN108159045B (en) application of robinine A and derivatives thereof in preparation of medicines for preventing or treating central nervous system diseases
CN114209716B (en) Application of modified lysosome in preparing medicines for treating protein misfolding or processing diseases
CN104224808B (en) Minocycline is used for the protective effect for offspring&#39;s Cerebral impairment that gestation stress be caused
US11510957B2 (en) Method for treating or alleviating autoimmune-related diseases
John et al. Astrogliosis and associated CSPG upregulation adversely affect dendritogenesis, spinogenesis and synaptic activity in the cerebellum of a double-hit rat model of protein malnutrition (PMN) and lipopolysaccharide (LPS) induced bacterial infection
CN111407768A (en) Application of composition in nerve injury protection field
Lai et al. Methylazoxymethanol acetate: effect of postnatal injection on brain amines and behavior
CN114392266B (en) Pharmaceutical composition containing PPAR gamma inhibitor and application thereof
US11963969B2 (en) Method for prevention or treatment of amyotrophic lateral sclerosis by administering gastrodin
KR102329305B1 (en) Huntington&#39;s disease treatment or prevention composition comprising human leukocyte antigen homozygous pluripotent stem cell-derived neural precursor cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination